SCHEMBL9944268

SCHEMBL9944268

CC(C)(C)/C=N/N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.41
LMNA P02545 4/20 0.41
GAA P10253 3/20 0.39
PKM P14618 1/20 0.39
POLB P06746 2/20 0.38
MAPT P10636 6/20 0.37
ALDH1A1 P00352 5/20 0.37
NPC1 O15118 4/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
KDM4E B2RXH2 3/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
APEX1 P27695 1/20 0.36
MPI P34949 1/20 0.36
NFKB1 P19838 1/20 0.36
CASP3 P42574 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22882612 0.79 MAPT (0.40) RAB9ALMNAGAAPKMPOLB
SCHEMBL22882610 0.78 MEN1 (0.32) L3MBTL1MEN1KMT2A
SCHEMBL22882607 0.76 MEN1 (0.35) RAB9ALMNAGAAPOLBALDH1A1
SCHEMBL9975293 0.73
SCHEMBL6960389 0.68 RAB9A (0.41) RAB9ALMNAGAAPKMPOLB
Bromide SCHEMBL1819096 0.67 POLB (0.40) RAB9ALMNAGAAPKMPOLB
SCHEMBL3535851 0.64
SCHEMBL7088098 0.64 POLB (0.38) RAB9ALMNAGAAPKMPOLB
SCHEMBL657078 0.64 POLB (0.38) RAB9ALMNAGAAPKMPOLB
SCHEMBL8636567 0.64 POLB (0.38) RAB9ALMNAGAAPKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216346-A1 Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same THE WISTAR INST (US) 2024-07-04 US disclosed
US-20240216346-A1 Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same THE WISTAR INST (US) 2024-07-04 US disclosed
US-11833137-B2 Substituted chromenones, IRE1 inhibitors, and methods of using same THE WISTAR INSTITUTE (US) 2023-12-05 US disclosed
US-11833137-B2 Substituted chromenones, IRE1 inhibitors, and methods of using same THE WISTAR INSTITUTE (US) 2023-12-05 US disclosed
US-20210008043-A1 Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same NATIONAL INSTITUTES OF HEALTH 2021-01-14 US disclosed
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US disclosed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME HIF1A, HIF1AN, EGLN3 RAB9A 3845/4885LMNA 1936/4885GAA 2071/4885
US-20210008043-A1 Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same XBP1, ERN1, ERN2 RAB9A 4421/4885LMNA 1588/4885GAA 3230/4885
US-11833137-B2 Substituted chromenones, IRE1 inhibitors, and methods of using same XBP1, ERN1, ERN2 RAB9A 4421/4885LMNA 1588/4885GAA 3230/4885
US-20240216346-A1 Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same XBP1, ERN1, ERN2 RAB9A 4337/4885LMNA 1674/4885GAA 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.